Aglaris Appoints New CEO
Aglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
David Horna, co-Founder and COO Aglaris said, We are pleased to have Steven on board. His extensive experience in innovative tools development and commercialisation will enable us to fast-track the delivery of our unique cell expansion system, Facer, and help the industry to bring these revolutionary therapeutics [1] to patients around the world.
Steven Docksey, CEO Aglaris added, Im excited to be joining the team at Aglaris as it is poised to revolutionise the manufacture of these vital cell-based therapies. With the explosion in CBT activity in the search for more effective regenerative medicines, being able to address the key industry issues of quality and consistency is imperative.
Previously, Steven held senior leadership and operational roles with Merck Millipore, Sartorius Stedim and GE Healthcare. Most recently he was adviser and Non-Executive Director at Puridify Ltd and was instrumental in its sale to GE Healthcare.